IL33 and systemic sclerosis: In SSc, increased cytokine production, particularly IL-33, at sites of injury and onset has shown to enhance endothelial cell activity, permeability, and angiogenesis [21], likely through recruitment and stimulation of immune cells, fibroblasts, and myofibroblast expressing ST2 [22].